1-Methyl-3-phenylazepane | 118576-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 1-Methyl-3-phenylazepane
• CAS: 118576-92-4
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: FTWKAHYVKOSDON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-苯基哌啶 在 cesium fluoride 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 54.0h， 生成 1-Methyl-3-phenylazepane
  参考文献：
  名称：

  Rearrangement of 1-methyl-2-(substituted-phenyl)piperidinium 1-methylides in a neutral medium

  摘要：

  DOI：

  10.1021/jo00265a022

文献信息

• [EN] HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2020247504A1

  公开（公告）日：2020-12-10

  Provided herein are compounds of formula (I) which comprise a thiomorpholine 1,1-dioxide or 1-imino-thiomorpholine 1-oxide moiety, or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including salts of the compound) and methods of synthesizing the same. Also provided are methods of treating Hepatitis B viral (HBV) infections using a compound of formula (I), or pharmaceutically acceptable salts thereof.

  本文提供了以下式(I)的化合物，其中包括硫吗啉1,1-二氧化物或1-亚硫酰吗啉1-氧化物基团，或者上述任何一种的药学上可接受的盐，包括描述的化合物（包括盐）的药物组合物以及合成它们的方法。还提供了使用式(I)的化合物或其药学上可接受的盐治疗乙型肝炎病毒（HBV）感染的方法。
• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION
  申请人：UNIV EDINBURGH

  公开号：WO2009112845A1

  公开（公告）日：2009-09-17

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺-噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）的作用。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物，在体内和体外，抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。
• [EN] AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS<br/>[FR] COMPOSÉS AMIDO-ISOTHIAZOLE ET LEUR UTILISATION COMME INHIBITEURS DE LA 11 ?-HSD1 DANS LE TRAITEMENT DU SYNDROME MÉTABOLIQUE ET DES TROUBLES APPARENTÉS
  申请人：UNIV EDINBURGH

  公开号：WO2010146338A1

  公开（公告）日：2010-12-23

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些酰胺异硫唑化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物，无论在体外还是体内，来抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1得到改善的疾病；治疗代谢综合征，其中包括疾病，如2型糖尿病和肥胖症，以及相关疾病，包括胰岛素抵抗、高血压、血脂紊乱和心血管疾病，如缺血性（冠状动脉）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。
• Conjugated-triene intermediates in the Sommelet-Hauser rearrangement of cyclic 1-methyl-2-phenylammonium 1-methylides.
  作者：Fumihiko SUMIYA、Naohiro SHIRAI、Yoshiro SATO

  DOI：10.1248/cpb.39.36

  日期：——

  Fluoride ion-induced desilylation of 1-methyl-1-(trimethylsilyl)methyl-2-(2-substituted phenyl)pyrrolidinium (3a), -piperidinium (3b and 3c), and -perhydroazepinium iodides (3d and 3e) gave high yields of eight- (5a), nine- (5b and 5c), and ten-membered cyclic amines (5d, 5e, 6d and 6e), containing conjugated-triene bond systems. These triene products are intermediates in the Sommelt-Hauser rearrangement of cyclic 1-methyl-2-phenylammonium 1-methylides (4), and were isomerized to the corresponding Sommelet-Hauser rearrangement products (7) in the presence of a strong base or an acid (except for 5b). Heating of these trienes in xylene yielded mixtures of the Stevens rearrangement products (8) and ring-opened amines (9). Selective formation of 8 was achieved by ultraviolet irradiation of the trienes (5) in hexane. The reaction mechanisms are discussed.

  氟离子诱导的 1-甲基-1-(三甲基硅烷基)甲基-2-(2-取代苯基)吡咯烷鎓（3a）、-哌啶鎓（3b 和 3c）和-全氢氮杂卓鎓碘化物（3d 和 3e）的脱硅反应和-全氢氮杂卓碘化物（3d 和 3e），高产率地得到了含有共轭三烯键系统的八元环胺（5a）、九元环胺（5b 和 5c）和十元环胺（5d、5e、6d 和 6e）。这些三烯产物是环状 1-甲基-2-苯基铵 1-甲基化物（4）的 Sommelt-Hauser 重排的中间产物，在强碱或强酸（5b 除外）的存在下，可异构化成相应的 Sommelet-Hauser 重排产物（7）。在二甲苯中加热这些三烯，可得到斯蒂文斯重排产物（8）和开环胺（9）的混合物。在己烷中用紫外线照射三烯（5），可以选择性地生成 8。本文对反应机理进行了讨论。
• Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders
  申请人：Webster Scott Peter

  公开号：US20120095046A1

  公开（公告）日：2012-04-19

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺异噻唑化合物，其在其他方面抑制11β-羟基类固醇脱氢酶1型（11β-HSD1）。本发明还涉及包括这些化合物的制药组合物，并且在体内外使用这些化合物和组合物以抑制11β-羟基类固醇脱氢酶1型；治疗通过抑制11β-羟基类固醇脱氢酶1型改善的疾病；治疗代谢综合症，包括2型糖尿病和肥胖症，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢紊乱和缺血性（冠状动脉）心脏病等；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。